SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Mineralys Therapeutics, Inc. (MLYS) has a negative trailing P/E of -14.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 11.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -6.98%, forward earnings yield 9.06%. PEG 0.10 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (94/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.10); analyst target implies upside (+68.4%).
- Forward P/E 11.0 — analysts expect a return to profitability with estimated EPS of $2.48 for FY2029.
- PEG Ratio 0.10 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -6.98% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 9.06% as earnings recover.
- Analyst consensus target $46.00 (+68.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
94/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MLYS
Valuation Multiples
P/E (TTM)-14.3
Forward P/E11.0
PEG Ratio0.10
Forward PEG0.10
P/B Ratio3.43
P/S Ratio0.00
EV/EBITDA-9.9
Per Share Data
EPS (TTM)$-1.92
Forward EPS (Est.)$2.48
Book Value / Share$8.03
Revenue / Share$0.00
FCF / Share$-1.77
Yields & Fair Value
Earnings Yield-6.98%
Forward Earnings Yield9.06%
Dividend Yield0.00%
Analyst Target$46.00 (+68.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
-24.9 |
0.00 |
-23.74 |
0.00 |
- |
| 2021 |
-4.7 |
-0.01 |
-4.01 |
0.00 |
- |
| 2022 |
-3.2 |
-0.07 |
-1.82 |
0.00 |
- |
| 2023 |
-4.3 |
0.07 |
1.29 |
0.00 |
- |
| 2024 |
-3.4 |
-0.04 |
3.12 |
0.00 |
- |
| 2025 |
-15.9 |
0.42 |
3.80 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$-0.09 |
$0.00 |
$-3.43M |
- |
| 2021 |
$-0.50 |
$0.00 |
$-19.41M |
- |
| 2022 |
$-0.73 |
$0.00 |
$-29.8M |
- |
| 2023 |
$-1.99 |
$0.00 |
$-71.9M |
- |
| 2024 |
$-3.66 |
$0.00 |
$-177.81M |
- |
| 2025 |
$-2.29 |
$0.00 |
$-154.65M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-2.19 |
$-2.43 – $-2.06 |
$557.14K |
$347.11K – $1.21M |
5 |
| 2027 |
$-1.86 |
$-3.66 – $1.39 |
$118.04M |
$107.22M – $128.84M |
5 |
| 2028 |
$-0.94 |
$-1.58 – $-0.28 |
$254.11M |
$158.31M – $551.86M |
5 |
| 2029 |
$2.48 |
$1.26 – $6.25 |
$751.03M |
$467.9M – $1.63B |
1 |
| 2030 |
$5.23 |
$2.67 – $13.20 |
$1.26B |
$784.48M – $2.73B |
1 |
